Publications
5674 Results
- Journal / Conference
- Society of Surgical Oncology (March 22-25, 2023, Boston, MA), oral plenary
- Year
- 2023
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1801
Surgical outcomes of SWOG S1801: Neoadjuvant versus adjuvant pembrolizumab for resectable stage III-IV melanoma
- Journal / Conference
- Society of Surgical Oncology (March 22-25, 2023, Boston, MA), oral
- Year
- 2023
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1512
Neoadjuvant Pembrolizumab in Stage II-III Desmoplastic Melanoma (SWOG S1512): Surgical Considerations
- Journal / Conference
- Society for Clinical Trials (May 21-24, 2023, Baltimore, MD), poster
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery
Quality Metrics in an NCTN Network Group
- Journal / Conference
- Society for Clinical Trials (May 21-24, 2023, Baltimore, MD), poster
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery
Beyond Static Tables and Figures: Utilizing Technology to Make Tables and Figures Richer and More Interactive
- Journal / Conference
- Society for Clinical Trials (May 21-24, 2023, Baltimore, MD), poster
- Year
- 2023
- Research Committee(s)
- Lung
- Study Number(s)
- S1400
Addressing Challenges of Lab Data Collection and Automation in Lung-MAP
- Journal / Conference
- AACR Annual Meeting (April 14-19, 2023, Orlando, FL, poster
- Year
- 2023
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1616
Quantitative analysis of CD8 T cell-melanoma cell interactions in response and resistance to ipilimumab plus nivolumab: Biopsy analysis of SWOG S1616
- Journal / Conference
- American Association for Thoracic Surgery (May 6 - 9, 2023, Los Angeles, CA), oral plenary session
- Year
- 2023
- Research Committee(s)
- Lung
Lobar versus sublobar resection for peripheral clinical T1aN0 NSCLC: a secondary analysis of CALGB/Alliance 140503
- Journal / Conference
- AACR Annual Meeting (April 14-19, 2023, Orlando, FL), major symposium presentation, SESSION SY43 - Sex Hormones and Cancer
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials
- Journal / Conference
- ESMO (October 20-24, 2023, Madrid, Spain), LBA, accepted profferred paper presentation
- Year
- 2023
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1801
Pathological response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab for resectable stage IIIB-IV melanoma from SWOG S1801
- Journal / Conference
- ESMO (October 20-24, 2023, Madrid, Spain), poster
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/N1048